ES2178038T3 - Nuevos derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen. - Google Patents

Nuevos derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen.

Info

Publication number
ES2178038T3
ES2178038T3 ES97952999T ES97952999T ES2178038T3 ES 2178038 T3 ES2178038 T3 ES 2178038T3 ES 97952999 T ES97952999 T ES 97952999T ES 97952999 T ES97952999 T ES 97952999T ES 2178038 T3 ES2178038 T3 ES 2178038T3
Authority
ES
Spain
Prior art keywords
rent
bencilo
links
alkyl
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97952999T
Other languages
English (en)
Inventor
Jean-Claude Barriere
Georges Bashiardes
Jean-Christophe Carry
Michel Evers
Bruno Filoche
Serge Mignani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of ES2178038T3 publication Critical patent/ES2178038T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA INVENCION SE REFIERE A DERIVADOS DE CICLOSPORINA DE FORMULA GENERAL (I) EN LA QUE ALK ES ALQUILENO DE 2 A 6 C EN CADENA RECTA O RAMIFICADA O CICLOALQUILENO QUE CONTIENE DE 3 A 6 C Y R ES: BIEN OH, COOH O ALQUILOXICARBONILO, O BIEN NR 1 R 2 PARA EL CUAL R 1 , R 2 IDENTICOS O DIFERENTES SON H, O ALQUILO, ALCENILO (2 A 4 C), CICLOALQUILO (3 A 6 C), FENILO OPCIONALMENTE SUSTITUIDO (POR HALOGENO, ALQUILOXILO, ALQUILOXICARBONILO, AMINO, ALQUILAMINO O DIALQUILAMINO) O SON RADICALES BENCILO O HETEROCICLILO SATURADO O INSATURADO QUE CONTIENE 5 O 6 ESLABONES Y 1 A 3 HETEROATOMOS O PARA EL CUAL R SUB,1 Y R 2 FORMAN CON EL ATOMO DE NITROGENO AL QUE ESTAN U NIDOS UN HETEROCICLO QUE CONTIENE DE 4 A 6 ESLABONES QUE PUEDEN CONTENER OTRO HETEROATOMO ELEGIDO ENTRE N, O O S Y OPCIONALMENTE SUSTITUIDO POR ALQUILO, FENILO O BENCILO, BIEN UN RADICAL DE FORMULA GENERAL (I'') PARA EL CUAL R 1 Y R 2 ESTAN DEFINIDO COMO ANTERIORMENTE, R 3 ES H O ALQUILO Y N ES UN NUMERO ENTERO DE 2 A 4, SIENDO LAS PARTES O RADICALES DE ALQUILO DEFINIDOS ANTERIORMENTE RECTOS O RAMIFICADOS Y CONTENIENDO ENTRE 1 Y 4 ATOMOS DE CARBONO, ASI COMO SUS SALES FARMACEUTICAMENTE ACEPTABLES CUANDO EXISTEN. ESTOS NUEVOS PRODUCTOS SON PARTICULARMENTE UTILES PARA EL TRATAMIENTO Y/O LA PROFILAXIS DE LAS INFECCIONES CON RETROVIRUS.
ES97952999T 1996-12-24 1997-12-23 Nuevos derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen. Expired - Lifetime ES2178038T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9615955A FR2757521B1 (fr) 1996-12-24 1996-12-24 Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
ES2178038T3 true ES2178038T3 (es) 2002-12-16

Family

ID=9499088

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97952999T Expired - Lifetime ES2178038T3 (es) 1996-12-24 1997-12-23 Nuevos derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen.

Country Status (14)

Country Link
US (1) US5994299A (es)
EP (1) EP0951474B1 (es)
JP (1) JP4146518B2 (es)
AT (1) ATE218582T1 (es)
AU (1) AU5669398A (es)
DE (1) DE69713152D1 (es)
DK (1) DK0951474T3 (es)
ES (1) ES2178038T3 (es)
FR (1) FR2757521B1 (es)
MA (1) MA26458A1 (es)
PT (1) PT951474E (es)
TN (1) TNSN97212A1 (es)
WO (1) WO1998028330A1 (es)
ZA (1) ZA9711607B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
CN1205220C (zh) * 1998-06-12 2005-06-08 斯－凯穆公司 新颖的环孢菌素
FR2780061B1 (fr) * 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
AU759480B2 (en) 1998-07-01 2003-04-17 Debiopharm S.A. Novel cyclosporin with improved activity profile
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6593292B1 (en) 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
KR100465012B1 (ko) * 2001-05-11 2005-01-13 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
IL160761A0 (en) * 2001-10-19 2004-08-31 Isotechnika Inc Novel cyclosporin analog microemulsion preconcentrates
MXPA04003625A (es) 2001-10-19 2004-12-02 Sotechnika Inc Sintesis de analogos de ciclosporina.
KR20040039622A (ko) * 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
US6987090B2 (en) * 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
US7538084B2 (en) 2003-03-17 2009-05-26 Amr Technology, Inc. Cyclosporins
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US7780973B2 (en) * 2003-12-15 2010-08-24 Ethicon Endo-Surgery, Inc. Method and device for minimally invasive implantation of biomaterial
US20050142161A1 (en) * 2003-12-30 2005-06-30 Freeman Lynetta J. Collagen matrix for soft tissue augmentation
US7671017B2 (en) * 2004-07-14 2010-03-02 Novartis Ag Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV)
KR100597309B1 (ko) 2004-09-17 2006-07-05 주식회사 핸슨바이오텍 세베키아 베니하나를 이용한 [감마 히드록실메틸루신4] 사이클로스포린 a의 제조방법
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
JP2008514701A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
SI1802650T1 (sl) * 2004-10-01 2012-03-30 Scynexis Inc Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
JP2008515886A (ja) 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
US7691812B2 (en) * 2004-11-04 2010-04-06 Trustees Of The University Of Pennsylvania Methods for inhibiting growth of prolactin-responsive cancer cells with cyclosporine A or other cyclophilin inhibitors
AU2005322241B2 (en) * 2004-12-23 2010-02-18 Novartis Ag Compounds for flaviviridae treatment
WO2006071619A1 (en) * 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment
CN101316606B (zh) * 2005-09-30 2015-05-27 西尼克斯公司 治疗和预防丙型肝炎感染的方法和药物组合物
JP5517454B2 (ja) * 2005-09-30 2014-06-11 スシネキス インク Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物
EP1931696B1 (en) 2005-09-30 2011-02-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
CN101502196A (zh) * 2006-06-02 2009-08-05 克洛德·安妮·佩里西恩 激活电子的管理
CA2665415A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Use of modified cyclosporins
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
US8394763B2 (en) 2007-09-26 2013-03-12 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
CN102083852A (zh) 2008-06-06 2011-06-01 西尼克斯公司 环孢菌素类似物及其在治疗hcv感染中的应用
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
JP5661035B2 (ja) * 2008-07-10 2015-01-28 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼および皮膚の疾患および症状の治療用のシクロスポリン誘導体
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
EP2376524B1 (en) 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
JP2012514605A (ja) * 2009-01-07 2012-06-28 サイネクシス，インコーポレーテッド Ｈｃｖおよびｈｉｖ感染の治療への使用におけるシクロスポリン誘導体
AU2010254316A1 (en) 2009-05-27 2011-12-22 Allergan, Inc. Cyclosporin derivatives for treating inflammatory diseases and conditions
WO2011082289A1 (en) 2009-12-30 2011-07-07 Scynexis Inc. Cyclosporine analogues
WO2012009715A2 (en) 2010-07-16 2012-01-19 S&T Global Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
US9573978B2 (en) 2010-08-12 2017-02-21 S&T Global, Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
JP5805774B2 (ja) 2010-10-12 2015-11-10 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンアナログ
CA2814191A1 (en) * 2010-10-12 2012-04-19 Allergan, Inc. Cyclosporin analogs
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
BR112013014890B1 (pt) 2010-12-15 2023-10-24 Contravir Pharmaceuticals, Inc Composto análogo de moléculas pertencentes à família ciclosporina, composição farmacêutica compreendendo o mesmo, uso terapêutico ou profilático do referido composto e processos para a preparação dos mesmos
EP2705856A1 (en) 2012-09-07 2014-03-12 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. Compounds for the treatment of neurodegenerative disorders
WO2020037530A1 (en) * 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
WO2020118714A1 (en) 2018-12-14 2020-06-18 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Maleate of scy-635 and uses thereof in medicine
WO2020118715A1 (en) * 2018-12-14 2020-06-18 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Salts of scy-635 and uses thereof in medicine
JP7764612B2 (ja) * 2021-12-09 2025-11-05 中美華世通生物医薬科技（武漢）股▲ふん▼有限公司 医薬におけるｗｓ６３５の使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4814323A (en) * 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
FI111730B (fi) * 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
PL324531A1 (en) * 1995-07-17 1998-06-08 Chem Ag C Derivatives of cyclosporin effective against hiv virus

Also Published As

Publication number Publication date
TNSN97212A1 (fr) 2005-03-15
FR2757521A1 (fr) 1998-06-26
JP4146518B2 (ja) 2008-09-10
MA26458A1 (fr) 2004-12-20
ZA9711607B (en) 1998-06-24
EP0951474A1 (fr) 1999-10-27
WO1998028330A1 (fr) 1998-07-02
DE69713152D1 (de) 2002-07-11
JP2001507347A (ja) 2001-06-05
DK0951474T3 (da) 2002-09-16
AU5669398A (en) 1998-07-17
ATE218582T1 (de) 2002-06-15
FR2757521B1 (fr) 1999-01-29
PT951474E (pt) 2002-11-29
EP0951474B1 (fr) 2002-06-05
US5994299A (en) 1999-11-30

Similar Documents

Publication Publication Date Title
ES2178038T3 (es) Nuevos derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen.
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
PA8472301A1 (es) Derivados de isotiazol utiles como agentes anticancerosos
ES2084944T3 (es) Amidas terapeuticas.
ES2076935T3 (es) Compuesto de pirazolopiridina y procedimientos para su preparacion.
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
CU23132A3 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
ES2070126T3 (es) Derivados de piridazinamina.
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
AR018033A1 (es) Analogos 13-oxa prostaglandinas, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento
PE108898A1 (es) Derivados 6,5-heterobiciclicos sustituidos
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
ES2161290T3 (es) Derivados de quinazolina.
ES2179996T3 (es) Cefalosporinas de vinil-pirrolidinona con sustituyentes basicos.
AR003453A1 (es) Inhibidores de agregado de plaquetas, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene y procedimiento para la preparacion de dichos inhibidores
UY28692A1 (es) Nuevos derivados de quinolina
PA8556801A1 (es) Compuestos de imidazopiridin como moduladores de receptor 5-ht 4
SV2003000697A (es) Agonistas del receptor beta3-adrenergico y usos de los mismos ref. pc11008/700016/bb
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
CO4810375A1 (es) Derivados de 9-amino-3-ceto eritromicina
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
EE200000059A (et) Tetrahüdro-gamma-karboliinid
ES2188743T3 (es) Compuestos de acido pirrolidinilhidroxamico y procedimiento de produccion de los mismos.
ES2056073T3 (es) Aril-aralquil-eteres, procedimientos para su preparacion y composicion farmaceutica que los comprende.